SCHEDULE: OrbiMed Amends Avalo Therapeutics Stake

OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC filed an amended Schedule 13G, updating their beneficial ownership in Avalo Therapeutics, Inc.

Summary

• OrbiMed Advisors LLC reported beneficial ownership of 967,000 shares of Avalo Therapeutics, Inc. Common Stock, representing 8.9% of the class.
• OrbiMed Capital GP IX LLC reported beneficial ownership of 644,667 shares of Avalo Therapeutics, Inc. Common Stock, representing 6.0% of the class.
• Both entities share voting and dispositive power over their respective reported shares.
• The filing is an Amendment No. 1 to a previously filed Schedule 13G.
• The shares were not acquired for the purpose of changing or influencing control of Avalo Therapeutics, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership, providing no inherent positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment firm in a publicly traded biotechnology company. It reflects an investment position rather than operational or strategic news from the issuer.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership and potential influence, though the filing explicitly states the shares were not acquired for control purposes.

Key Dates

Keywords

Avalo Therapeutics, OrbiMed Advisors, OrbiMed Capital, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Biotechnology